Non-inferiority study comparing Zanubrutinib vs. Bendamustine

 Back  View
Non-inferiority study comparing Zanubrutinib vs. Bendamustine
 IMAGE   06/2020
 View

Non-inferiority study comparing Zanubrutinib + Rituximab vs. Bendamustine + Rituximab as 1L treatment in MCL

Rating

Rate this resource

Related resources

Zanubrutinib - Mode of Action
Zanubrutinib - Mode of Action
EHA2021 - WM and MZL - disease, diagnosis and the role of TLR/BCR pathway
EHA2021 - WM and MZL - disease, diagnosis and the role of TLR/BCR pathway
Zanubrutinib in Previously Treated CLL/SLL, MCL, MZL, or WM Intolerant to Ibrutinib/Acalabrutinib
Zanubrutinib in Previously Treated CLL/SLL, MCL, MZL, or WM Intolerant to Ibrutinib/Acalabrutinib
 Back